Recombinant Interleukin-11
Gestational Trophoblastic Neoplasm
Explore 6 assets in Gestational Trophoblastic Neoplasm →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00004157CT.gov Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gestational Trophoblastic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Interleukin-11 (this asset) | Fred Hutchinson Cancer Center | P2 | B · 57 |
| Amifostine | Gynecologic Oncology Group | P3 | B |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
| Alemtuzumab | Fred Hutchinson Cancer Center | P2 | B |
| Moxifloxacin | OHSU Knight Cancer Institute | P3 | B |
| Sargramostim | Cancer Treatment Centers of America | P2 | B |
| Alpha-Interferon | Cancer Treatment Centers of America | P2 | B |
| Tacrolimus | Case Comprehensive Cancer Center | P2 | B |
| Ondansetron | Fred Hutchinson Cancer Center | P2 | B |
+17 more in the Gestational Trophoblastic Neoplasm cohort
Other indications for Recombinant Interleukin-11
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Testicular Germ Cell Tumor | — | P2 | B · 57 |
| Neuroblastoma | — | P2 | B · 57 |
| Kidney Cancer | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Interleukin-11 in Gestational Trophoblastic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-interleukin-11-gestational-trophoblastic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →